€ 8.3
Key Takeaways
Risk factor
Very poor trading liquidity
Profitability factor
Very favourable analyst view
About
Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Ireland and the United States. It offers life-saving cell and gene therapies for patients with high unmet medical need; medicines to address unmet needs in cancer, infection, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health...
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of MLC.IR is 16 and suggests 87% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
